Stifel Financial Corp Compugen LTD Transaction History

Stifel Financial Corp

$86.8 Billion
Q2 2024

A detailed history of Stifel Financial Corp transactions in Compugen LTD stock. As of the latest transaction made, Stifel Financial Corp holds 51,659 shares of CGEN stock, worth $84,720. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,659

Previous 52,762 2.09%

Holding current value

$84,720

Previous $136,000 36.76%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.68 - $2.52 $1,853 - $2,779	-1,103 Reduced 2.09%	51,659 $86,000
Q1 2024 May 13, 2024	BUY	$1.75 - $2.95 $3,942 - $6,646	2,253 Added 4.46%	52,762 $136,000
Q4 2023 Feb 12, 2024	BUY	$0.53 - $2.0 $710 - $2,680	1,340 Added 2.73%	50,509 $100,000
Q3 2023 Nov 13, 2023	BUY	$0.88 - $1.31 $33 - $49	38 Added 0.08%	49,169 $45,000
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.38 $554 - $1,341	972 Added 2.02%	49,131 $56,000
Q1 2023 May 12, 2023	BUY	$0.68 - $1.11 $1,039 - $1,697	1,529 Added 3.28%	48,159 $33,000
Q4 2022 Feb 13, 2023	SELL	$0.58 - $1.2 $26 - $55	-46 Reduced 0.1%	46,630 $33,000
Q3 2022 Nov 14, 2022	SELL	$0.66 - $2.32 $105 - $371	-160 Reduced 0.34%	46,676 $31,000
Q2 2022 Aug 15, 2022	BUY	$1.57 - $3.33 $131 - $279	84 Added 0.18%	46,836 $87,000
Q1 2022 May 13, 2022	BUY	$2.76 - $4.64 $31,072 - $52,237	11,258 Added 31.72%	46,752 $151,000
Q4 2021 Feb 14, 2022	BUY	$4.09 - $7.16 $145,170 - $254,137	35,494 New	35,494 $153,000
Q4 2020 Feb 12, 2021	SELL	$12.07 - $17.95 $137,006 - $203,750	-11,351 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$14.16 - $19.45 $160,730 - $220,776	11,351 New	11,351 $184,000

Others Institutions Holding CGEN

# of Institutions

Shares Held

13.3M

Call Options Held

191K

Put Options Held

135K

View Full List

About COMPUGEN LTD

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $142M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

More about CGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Account

Stifel Financial Corp Compugen LTD Transaction History